Alzheon’s oral anti-amyloid drug has potential to be first oral Aβ-targeting therapy approved in US…
Alzheon has recently presented promising interim results from its Phase II Biomarker Trial (NCT04693520) of its oral,…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.